Piper Jaffray Upgrades Onconova Therapeutics To Overweight

Piper Jaffray upgraded

from Neutral to Overweight. The price target for Onconova Therapeutics has been raised from $3.00 to $6.00. Onconova Therapeutics shares have dropped 55.28 percent over the past 52 weeks, while the S&P 500 index has surged 4.48 percent in the same period. Onconova Therapeutics' shares closed at $2.37 yesterday.